Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis C

Journal of Infectious Diseases

Volumn 203, Issue 5, 2011, Pages 595-601

  Nattermann, Jacob ^a   Vogel, Martin ^a   Nischalke, Hans Dieter ^a   Danta, Mark ^l   Mauss, Stefan ^b   Stellbrink, Hans Jörg ^c   Baumgarten, Axel ^e   Mayr, Christoph ^f   Bruno, Raffaele ^m   Tural, Cristina ⁿ   Klausen, Gerd ^g   Clotet, Bonaventura ⁿ   Naumann, Uwe ^c   Lutz, Thomas ^j   Rausch, Michael ^h   Schewe, Knud ^d   Bienek, Bernhard ⁱ   Haerter, Georg ^k   Sauerbruch, Tilman ^a   Rockstroh, Juergen K ^a   Spengler, Ulrich ^a   more..

^a UNIVERSITY OF BONN   (Germany)

^b Center for HIV and Hepatogastroenterology   (Germany)

^c Infektionsmedizinisches Centrum Hamburg   (Germany)

^d DEPARTMENT OF CARDIOLOGY   (Germany)

^e Practice Dupke/Carganico/Baumgarten   (Germany)

^f Practice Aerzteforum Seestraße   (Germany)

^g Praxiszentrum Kaiserdamm   (Germany)

^h Practice Freiwald/Rausch   (Germany)

ⁱ Practice Bieniek/Cordes   (Germany)

^j HIV cohort Frankfurt   (Germany)

^k UNIVERSITY HOSPITAL ULM   (Germany)

^l ST VINCENT'S CLINIC   (Australia)

^m UNIVERSITY OF PAVIA   (Italy)

ⁿ HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 28B; RIBAVIRIN; VIRUS RNA;

ACUTE HEPATITIS; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHRONIC HEPATITIS; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VIRAL CLEARANCE;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; REGRESSION ANALYSIS; RNA, VIRAL; TREATMENT OUTCOME;

EID: 79751511058     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq098     Document Type: Article

References (15)

1. Rockstroh JK, Spengler U. HIV and hepatitis C virus co-infection. Lancet Infect Dis 2004; 4:437-44. (Pubitemid 38844128)
2. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002; 136:288-92. (Pubitemid 34150758)
3. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41:1100-4.
4. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.
5. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
6. McCarthy JJ, Li JH, Thompson A, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138:2307-14.
7. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment Failure: a Genome-wide association study. Gastroenterology 2010; 138:1338-45.
8. Rallón NI, Naggie S, Benito JM, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010; 24:F23-9.
9. Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345: 1452-7.
10. Rockstroh JK, Bhagani S, Benhamou Y, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008; 9:82-8. (Pubitemid 351228130)
11. Vogel M, Nattermann J, Baumgarten A, et al. Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals. Antivir Ther 2006; 11:1097-101. (Pubitemid 44955186)
12. Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4:69-77. (Pubitemid 36109115)
13. Marcello T, Grakoui A, Barba-Spaeth G, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131: 1887-98. (Pubitemid 44958521)
14. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 2008; 105:7034-9. (Pubitemid 351754525)
15. Honda M, Sakai A, Yamashita T, et al. Hepatic ISG expression is associated with genetic variation in IL28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010. [Epub ahead of print].